Investor Presentation

Delivering Customer and Shareholder Value Disruptive technologies and expanding markets are driving diversification... 3 DEPLIO G00 Tomer's SAS G EXPOSED LIFT R REPLIGEN XCell ATF 1 LIFT REPLIGEN P REPLIGEN ProConnex TFDF Flow Path Solo $CTECHNOLOGIES, INC. VPE R REPLIGEN OPUS 80R I > Solutions for viral vector, mAb, rPr, vaccine manufacturing ... and increased revenue and profitability Revenue (in $Ms) $800 ** $700 $600 $500 $400 $300 $200 $100 $0 2017-2020 37% 3-year Revenue CAGR $0.58 $141.1 $0.66 $193.9 2.8x increase in Adj. EPS $1.07 R REPLIGEN INSPIRING ADVANCES IN BIOPROCESSING $270.2 $1.65 $366.0 $2.89 $660.0 FY 18* FY 19* FY 17* FY 20 *Change in accounting for the treatment of tax on certain non-GAPP adjustments Adj. EPS is a non-GAAP financial measure; see reconciliations in Appendix *** FY 2021 Guidance at midpoint as of 10/28/21 earnings call *** FY 21G* $3.50 $3.00 $2.50 $2.00 $1.50 $1.00 $0.50 $0.00 Adj. EPS fully diluted ** 6

View entire presentation